How to Select the Bi-Specific mAb For the Treatment of RRMM?
Time: 2:00 pm
day: Day Two
- Patient and disease-based factors should drive the treatment decision making
- Bi-specific mAbs are off the shelf-drugs that will present wide availability
- Bi-specific mAbs might be combined wih other mABs or IMiD’s to complement the treatment strategies and improve outcomes